India Audits 1,100+ Cough Syrup Makers Amid Crackdown

India has inspected nearly 90% of its cough syrup manufacturers and taken 950+ regulatory actions — here’s what buyers sourcing from India need to know.

India’s drug regulator has inspected nearly 90% of the country’s cough syrup manufacturers — roughly 1,100 companies — and taken more than 950 regulatory actions since 2022, as the government works to restore confidence in a $42 billion pharmaceutical industry shaken by a string of contamination-linked child deaths.

The Scale of the Response

State licensing authorities have issued show cause notices, stop production orders, and suspended or cancelled licenses at manufacturing units found in violation. The inspections follow the discovery of diethylene glycol-contaminated cough syrup linked to child deaths in India, with India-made cough syrups tied to more than 140 child deaths across Africa and Central Asia since 2022 — a pattern that has damaged the country’s positioning as the “pharmacy of the world.”

What Inspectors Are Finding

Risk-based inspections have surfaced consistent quality failures: poor documentation, lack of process and analytical validation, absence of self-assessment and quality failure investigation, and failure to test incoming raw materials before use in manufacturing. In response, India has upgraded Good Manufacturing Practices under its Drugs and Cosmetics Rules, introducing quality risk management, supplier audit and approval, and equipment validation requirements — with large manufacturers given six months and small manufacturers twelve months to transition.

What This Means for Procurement Teams

Vendor qualification now needs to go deeper than certification checks. With inspectors repeatedly finding raw material testing failures and inadequate quality systems, buyers sourcing from Indian manufacturers should request evidence of the upgraded GMP compliance directly, not rely on historical certification status alone.

Smaller manufacturers carry elevated near-term risk. With small manufacturers given twelve months to transition to upgraded requirements, buyers working with smaller Indian suppliers should build in additional audit checkpoints during that transition window.

This reinforces the broader reshoring conversation. Combined with GDUFA IV’s onshoring incentives, sponsors weighing India against US/EU alternatives now have two converging signals — cost efficiency on one side, tightening compliance risk on the other — worth factoring into multi-year sourcing strategy.

FAQ

How many cough syrup manufacturers has India inspected?

India’s drug regulator has inspected nearly 90% of the country’s cough syrup makers, roughly 1,100 companies, taking more than 950 regulatory actions since 2022.

What quality failures were most commonly found?

Inspectors repeatedly identified poor documentation, lack of process validation, absence of quality failure investigation, and failure to test raw materials before manufacturing.

What compliance changes has India introduced in response?

India has upgraded its Good Manufacturing Practices to require quality risk management, supplier audit and approval, and equipment validation, with large manufacturers given six months and small manufacturers twelve months to comply.

Sources

• Economic Times, Govt Tightens Drug Quality Net, Initiates 950 Actions Since 2022
• Reuters via AOL, India’s Drug Regulator Inspected 90% of Cough Syrup Makers